Despite this engagement, only transient disease stabilization was observed and 23% of subjects developed grade 3-4 thrombocytopenia, indicating that indiscriminate depletion of FAP-positive CAFs may compromise microvascular integrity and limit therapeutic efficacy 223. This evidence concerns the gene FAP and Thrombocytopenia.